All Posts By

Smartkarma Daily Briefs

Daily Brief Credit: Road King – Earnings Flash – H1 FY 2022 Results – Lucror Analytics and more

By | Credit, Daily Briefs

In today’s briefing:

  • Road King – Earnings Flash – H1 FY 2022 Results – Lucror Analytics
  • Morning Views Asia: Guangzhou R&F Properties

Road King – Earnings Flash – H1 FY 2022 Results – Lucror Analytics

By Leonard Law, CFA

Road King’s H1/22 results were acceptable in our view. The company reported robust EBITDA growth and strong margin expansion, likely supported by deliveries of the higher-margin Hong Kong projects sold in FY 2021. Net debt improved marginally, in line with the stronger earnings.

That said, Cash/ST Debt was inadequate at 0.8x. Road King may face a funding gap for repayment of its USD 358 mn bonds in February 2023, though it should be able to bridge the gap through better cash collections in H2/22 or potential external financing (asset sales or equity issuances). Positively, the company has a well-spread debt maturity profile, with only one offshore bond coming due in 2023 and the next (USD 480 mn) due in September 2024.


Morning Views Asia: Guangzhou R&F Properties

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Quantitative Analysis: Hong Kong: Where Have Shorts Been Building Up? and more

By | Daily Briefs, Quantitative Analysis

In today’s briefing:

  • Hong Kong: Where Have Shorts Been Building Up?

Hong Kong: Where Have Shorts Been Building Up?

By Brian Freitas

  • Short notional in Hong Kong is HK$439bn and has been falling over the last 18 months due to a drop in the market.
  • In terms of short notional to issue market cap, the Information Technology, Materials, Health Care and Consumer Discretionary sectors are up there, with Communication Services, Real Estate the least shorted.
  • Over the year, the largest shorts in terms of notional have been built on Xiaomi Corp, Meituan, JD.com, AIA Group Ltd, Postal Savings Bank of China, Orient Overseas, Techtronic Industries.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Event-Driven: Pendal Group (PDL AU): Perpetual’s Bump Should Get the Deal Done and more

By | Daily Briefs, Event-Driven

In today’s briefing:

  • Pendal Group (PDL AU): Perpetual’s Bump Should Get the Deal Done
  • Ramsay’s Overdue Update on the KKR Proposal
  • Pendal Enters Scheme With Perpetual
  • Pendal Gets a Binding Offer from Perpetual
  • I Squared/FirstGroup: Why Have the Negotiations Ended?
  • STOXX Europe Quiddity Leaderboard Sep 2022: 11 ADDs/DELs, Sandvik-Alleima, and More

Pendal Group (PDL AU): Perpetual’s Bump Should Get the Deal Done

By Brian Freitas

  • Pendal Group and Perpetual Ltd have entered into a SID where Pendal shareholders will receive 1 share of Perpetual for every 7.5 shares in Pendal, plus cash of A$1.976/share.
  • While this is a premium to the last close and undisturbed prices, it is a discount to longer term prices. The Pendal Board has unanimously recommended the offer though.
  • In the short-term expect short covering on Pendal Group (PDL AU) and increased shorts on Perpetual Ltd (PPT AU) as arbs step in to close the gap.

Ramsay’s Overdue Update on the KKR Proposal

By Arun George

  • Ramsay Health Care (RHC AU) notes that discussions with KKR are ongoing, but the indicative proposal is held up by due diligence access to Ramsay Generale de Sante (GDS FP).
  • KKR proposed an alternative proposal that the Board rejected as “meaningfully inferior.” KKR remains interested, and its shenanigans are likely a move to nudge down the price.
  • At the last close, the risk/reward profile is favourable as the downside due to a deal break (-3% estimated decline) is lower than the upside (+20%) to the indicative proposal.

Pendal Enters Scheme With Perpetual

By David Blennerhassett

  • On the 4 April, asset manager Pendal (PDL AU)‘s board unanimously determined the indicative cash/scrip Offer proposal from Perpetual (PPT AU) undervalued the current and future value of the company.
  • Pendal And Perpetual have now entered into a SID such that Pendal shareholders will receive 1 Perpetual share for every 7.5 Pendal shares plus $1.976 cash for each Pendal share.
  • The negotiation clincher was the increase in the cash component by A$0.306/share. Should the deal complete, Pendal will hold 47% in the enlarged entity.

Pendal Gets a Binding Offer from Perpetual

By Arun George

  • Pendal Group (PDL AU) entered a scheme implementation deed with Perpetual Ltd (PPT AU). The revised offer – scrip (1 Perpetual share for every 7.5 Pendal share) and cash (A$1.976).
  • The revised offer throws in an 18.3% higher cash component as a sweetener. The offer implies a healthy acquisition multiple compared to peers.
  • The offer is subject to shareholder and regulatory approvals. At the last close price, the gross spread to the current offer value of A$5.635 per share is 13.7%.

I Squared/FirstGroup: Why Have the Negotiations Ended?

By Jesus Rodriguez Aguilar

  • On 16 August, I Squared confirmed it did not intend to make an offer for FirstGroup thus will now be precluded from bidding for six months.
  • The 15 August offer implied almost no premium for the core business, significant value not reflected, and a difficult to grasp structure for most investors, in my view.
  • A SOTP approach gives a fair value of 183.4p. The board seems right in its refusal. Other bidders may appear or I Squared may return to the negotiating table. Long.

STOXX Europe Quiddity Leaderboard Sep 2022: 11 ADDs/DELs, Sandvik-Alleima, and More

By Janaghan Jeyakumar, CFA

  • In this insight, we take a look at the names leading the race to become ADDs/DELs for the STOXX Europe 600 and EURO STOXX Indices for the September 2022 Rebalance.
  • Based on current rankings, there could be around 11 ADDs/DELs in the September 2022 Rebalance.
  • The completion of the Avast PLC (AVST LN) and Meggitt PLC (MGGT LN) deals could result in intra-review changes in September 2022.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Equity Bottom-Up: Escorts Kubota (ESCORTS IN) | Alarming Allegations by Dealers and more

By | Daily Briefs, Equity Bottom-Up

In today’s briefing:

  • Escorts Kubota (ESCORTS IN) | Alarming Allegations by Dealers
  • Taiwan Dual-Listings – TSMC Premium Continues to Decline, ChipMOS ADR Discount Widens
  • US CHIPS Act: Long Intel Vs. Short TSMC or UMC?
  • XL Axiata (EXCL IJ) – Following the Road to Convergence Fuelled by Data
  • Snowflake FY2Q23 Earnings: High in the Hierarchy of Needs
  • Helixmith (084990 KS): Overhang on Phase 3 Clinical Trial Uncertainty Got Removed
  • Edelweiss: Credit Business Is Normalizing; Rest of the Businesses Are Scaling Up Well
  • Sinotrans (598 HK): Still a Very Decent Performance
  • Imugene (IMU AU): Clinical Trial Continued to Advance; Cash Position Still Strong
  • Nike Inc: Innovation For The Pregnant Women Niche & Other Drivers

Escorts Kubota (ESCORTS IN) | Alarming Allegations by Dealers

By Pranav Bhavsar

  • Escorts Kubota (ESCORTS IN) ‘s domestic market share as of FY22 stood at 10.3 % vs 12% in FY20 against the aspiration of 15% for FY22. 
  • Our interactions with various dealers across key northern and eastern states suggest caution and structural inability to regain market share loss.
  • Post equity infusion, Kubota Corp (6326 JP) is probably in for more surprises than what it might have initially hoped for. 

Taiwan Dual-Listings – TSMC Premium Continues to Decline, ChipMOS ADR Discount Widens

By Vincent Fernando, CFA

  • TSMC’s ADR premium falls past the lower bound of its 3-year range
  • All dual-listed Taiwan semiconductor companies have seen a decline in premiums or an increase in discounts.
  • ChipMOS ADR’s discount to the company’s Taiwan listing widens further.

US CHIPS Act: Long Intel Vs. Short TSMC or UMC?

By Vincent Fernando, CFA

  • Intel and Brookefield Asset Management recently announced that they intend to jointly invest US$30 billion into building Intel foundries in Arizona, leveraging on the US CHIPS Act.
  • Although inflation and declining consumer demand continue to affect all chipmakers, U.S. strategic objectives and policies will set Intel on a new growth trajectory and competitive position in our view.
  • A Long Intel/ Short Taiwan semiconductor strategy present a compelling opportunity. We prefer Long Intel vs. Short UMC, however, we expect Long Intel vs. Short TSMC to also be profitable.

XL Axiata (EXCL IJ) – Following the Road to Convergence Fuelled by Data

By Angus Mackintosh

  • XL Axiata 2Q2022 results reflected a better pricing environment and the success of its focus on high-quality service, with the highest data speeds, leading to higher subs and ARPUs. 
  • The company continues to migrate its subscribers to 4G, and build out its 4G BTS whilst shutting down its 3G towers, which should be positive for the quality of service.
  • XL Axiata (EXCL IJ) should be seen as the leader in providing converged services in Indonesia, with the acquisition of Link Net accelerating its lead, which will boost long-term profitability.

Snowflake FY2Q23 Earnings: High in the Hierarchy of Needs

By Aaron Gabin

  • Product revenues beat consensus by 7% and EBIT margins by 5%, while full year guidance was and margins were raised ~2% ahead of consensus.
  • Fears of a consumption model driven slowdown (like Datadog) did not play out, and cRPO growth actually accelerated QoQ to 81%.
  • Data sharing is picking up with larger customers, with 65% of $1M+ customers utilizing stable edges.

Helixmith (084990 KS): Overhang on Phase 3 Clinical Trial Uncertainty Got Removed

By Tina Banerjee

  • Helixmith (084990 KS) shares have been sliding since end of June due to delay in receiving the recommendation from the U.S. data monitoring committee for its phase 3 clinical trial.
  • On August 18, Helixmith received recommendation to continue phase 3 clinical trial of its lead candidate Engensis (VM202) for diabetic peripheral neuropathy, thereby removing the overhang.
  • Engensis has attracted high interest from investors, as it is targeting a large addressable patient population of nearly 8.5 million in the U.S. alone, with high unmet medical need.  

Edelweiss: Credit Business Is Normalizing; Rest of the Businesses Are Scaling Up Well

By Ankit Agrawal, CFA

  • Edelweiss’ credit business is now normalizing with GNPA at 2.5% and NNPA at 1.8%. Credit costs came in negative as asset quality is improving and excess provisioning is being normalized. 
  • Rest of the businesses continue to scale up well. Edelweiss is among the fastest grower in the mutual fund and insurance businesses. Wealth Management business continues to do well.
  • At current valuation, Edelweiss is available cheap and as per our estimates, an investment in it has potential to more than quadruple by the end of FY25.

Sinotrans (598 HK): Still a Very Decent Performance

By Osbert Tang, CFA

  • Recurring profit for Sinotrans (598 HK) increased 16.4% in 1H22 and improved to 16.6% in 2Q22. The declaration of an interim dividend also highlights management’s confidence.
  • We expect a pick-up in 2H22 as negative impact of the lockdowns faded. Also, contribution from DHL-Sinotrans should return to growth as international express regain momentum.
  • Strong financial position should allow for higher dividend payout, and currently it is already yielding 10.4%. Its 3.6x PER and 0.4x P/B are cheap, especially relative to ROE of 11.3%.

Imugene (IMU AU): Clinical Trial Continued to Advance; Cash Position Still Strong

By Tina Banerjee

  • Imugene Ltd (IMU AU) has recently dosed the first patient in cohort 3 in the phase 1 clinical trial of oncolytic virotherapy candidate, CHECKvacc for breast cancer.
  • As at June 30, 2022, Imugene had cash balance of A$99.9 million, providing a runway to support its clinical pipeline and operations into 2025. 
  • As the clinical trials progressing, the company has appointed an experienced life sciences CFO.

Nike Inc: Innovation For The Pregnant Women Niche & Other Drivers

By Ishan Majumdar

  • Nike Inc had another stellar quarter and managed to surpass Wall Street expectations in terms of revenues as well as earnings with plenty of new innovations coming out.
  • A new lifestyle show, Nike Spark Flynit, was launched that introduces the latest innovation of NIKE Running with the Spark cushioning system.
  • This quarter, in Jordan, Luka Doncic debuted his anticipated signature shoe Luka 1, during the NBA Playoff.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Macro: BoE Remit Reforms and more

By | Daily Briefs, Macro

In today’s briefing:

  • BoE Remit Reforms
  • CX Daily: Four Things to Know About China’s Power Crunch

BoE Remit Reforms

By Phil Rush

  • The UK’s probable next Prime Minister is channelling frustration about high inflation towards a review of the Bank of England, raising the risk of a remit change.
  • Alternatives like average inflation and nominal GDP targeting remain undesirable, so a credible review will probably support the 2% inflation target.
  • Removing the distraction of supporting green objectives would be sensible politics. Restricting non-state dependent guidance would be more beneficial but is less likely.

CX Daily: Four Things to Know About China’s Power Crunch

By Caixin Global

  • Power crunch / Four things to know about China’s power crunch

  • Covid-19 / Trending in China: Police scorned online for punishing men attending funeral during lockdown

  • Economy / China rolls out more measures to stabilize economy


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief TMT/Internet: Softbank Group, Taiwan Semiconductor (TSMC) – ADR, Intel Corp, XL Axiata, Snowflake Inc, Paycom Software and more

By | Daily Briefs, TMT/Internet

In today’s briefing:

  • Softbank (9984 JP) – This Time, It’s Chime
  • Taiwan Dual-Listings – TSMC Premium Continues to Decline, ChipMOS ADR Discount Widens
  • US CHIPS Act: Long Intel Vs. Short TSMC or UMC?
  • XL Axiata (EXCL IJ) – Following the Road to Convergence Fuelled by Data
  • Snowflake FY2Q23 Earnings: High in the Hierarchy of Needs
  • Paycom Software: The Beti Upside

Softbank (9984 JP) – This Time, It’s Chime

By Victor Galliano

  • US fintech Chime, another high-profile fintech in Softbank’s Vision Fund 2 portfolio, sees its secondary market valuation in the private market fall by nearly 50% on a year-to-date basis
  • Chime had been planning to IPO in 1H 2022, with its IPO valuation estimated at close to USD40bn; poor market conditions have led to the IPO being shelved
  • Chime’s reduced valuation is another hit to Softbank’s portfolio, which has yet to feature a recent “down round”, and which we believe negatively impacts its Vision Fund 2 in particular

Taiwan Dual-Listings – TSMC Premium Continues to Decline, ChipMOS ADR Discount Widens

By Vincent Fernando, CFA

  • TSMC’s ADR premium falls past the lower bound of its 3-year range
  • All dual-listed Taiwan semiconductor companies have seen a decline in premiums or an increase in discounts.
  • ChipMOS ADR’s discount to the company’s Taiwan listing widens further.

US CHIPS Act: Long Intel Vs. Short TSMC or UMC?

By Vincent Fernando, CFA

  • Intel and Brookefield Asset Management recently announced that they intend to jointly invest US$30 billion into building Intel foundries in Arizona, leveraging on the US CHIPS Act.
  • Although inflation and declining consumer demand continue to affect all chipmakers, U.S. strategic objectives and policies will set Intel on a new growth trajectory and competitive position in our view.
  • A Long Intel/ Short Taiwan semiconductor strategy present a compelling opportunity. We prefer Long Intel vs. Short UMC, however, we expect Long Intel vs. Short TSMC to also be profitable.

XL Axiata (EXCL IJ) – Following the Road to Convergence Fuelled by Data

By Angus Mackintosh

  • XL Axiata 2Q2022 results reflected a better pricing environment and the success of its focus on high-quality service, with the highest data speeds, leading to higher subs and ARPUs. 
  • The company continues to migrate its subscribers to 4G, and build out its 4G BTS whilst shutting down its 3G towers, which should be positive for the quality of service.
  • XL Axiata (EXCL IJ) should be seen as the leader in providing converged services in Indonesia, with the acquisition of Link Net accelerating its lead, which will boost long-term profitability.

Snowflake FY2Q23 Earnings: High in the Hierarchy of Needs

By Aaron Gabin

  • Product revenues beat consensus by 7% and EBIT margins by 5%, while full year guidance was and margins were raised ~2% ahead of consensus.
  • Fears of a consumption model driven slowdown (like Datadog) did not play out, and cRPO growth actually accelerated QoQ to 81%.
  • Data sharing is picking up with larger customers, with 65% of $1M+ customers utilizing stable edges.

Paycom Software: The Beti Upside

By Ishan Majumdar

  • Paycom Software continues to witness a strong demand for automation of management of human capital and self-service payroll with more companies embracing its various solutions, especially Beti.
  • The success to attract new business wins as well as robust demand for employee-focused easy-to-use solutions, drives the company’s revenue growth.
  • We provide the stock of Paycom Software with a ‘Hold’ rating with a revision in the target price.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Utilities: Tokyo Stock Exchange Tokyo Price Index Topix and more

By | Daily Briefs, Utilities Sector

In today’s briefing:

  • More Companies Submitted Shareholder Proposals, but All Were Rejected. Where Is the Problem?

More Companies Submitted Shareholder Proposals, but All Were Rejected. Where Is the Problem?

By Aki Matsumoto

  • Even though shareholder proposals have increased, only 77 of the more than 2,000 companies with a fiscal year ending in March have submitted shareholder proposals, or only a few percent.
  • Japanese institutional investors begins to examine the content of proposals and exercise their voting rights. It’s serious matter that until now they haven’t exercised them in accordance with Stewardship Code.
  • It will still take substantial amount of time to move away from a shareholder meeting protected by a cross-shareholding structure and toward a shareholder meeting that promotes dialogue with shareholders.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Financials: Pendal Group, Link REIT, Edelweiss Financial Services, Road King Infrastructure, Guangzhou R&F Properties and more

By | Daily Briefs, Financials

In today’s briefing:

  • Pendal Group (PDL AU): Perpetual’s Bump Should Get the Deal Done
  • Pendal Enters Scheme With Perpetual
  • Pendal Gets a Binding Offer from Perpetual
  • HSI Properties, Link RIET, HSI Financials, China Merchants Bank, and ICBC
  • Edelweiss: Credit Business Is Normalizing; Rest of the Businesses Are Scaling Up Well
  • Road King – Earnings Flash – H1 FY 2022 Results – Lucror Analytics
  • Morning Views Asia: Guangzhou R&F Properties

Pendal Group (PDL AU): Perpetual’s Bump Should Get the Deal Done

By Brian Freitas

  • Pendal Group and Perpetual Ltd have entered into a SID where Pendal shareholders will receive 1 share of Perpetual for every 7.5 shares in Pendal, plus cash of A$1.976/share.
  • While this is a premium to the last close and undisturbed prices, it is a discount to longer term prices. The Pendal Board has unanimously recommended the offer though.
  • In the short-term expect short covering on Pendal Group (PDL AU) and increased shorts on Perpetual Ltd (PPT AU) as arbs step in to close the gap.

Pendal Enters Scheme With Perpetual

By David Blennerhassett

  • On the 4 April, asset manager Pendal (PDL AU)‘s board unanimously determined the indicative cash/scrip Offer proposal from Perpetual (PPT AU) undervalued the current and future value of the company.
  • Pendal And Perpetual have now entered into a SID such that Pendal shareholders will receive 1 Perpetual share for every 7.5 Pendal shares plus $1.976 cash for each Pendal share.
  • The negotiation clincher was the increase in the cash component by A$0.306/share. Should the deal complete, Pendal will hold 47% in the enlarged entity.

Pendal Gets a Binding Offer from Perpetual

By Arun George

  • Pendal Group (PDL AU) entered a scheme implementation deed with Perpetual Ltd (PPT AU). The revised offer – scrip (1 Perpetual share for every 7.5 Pendal share) and cash (A$1.976).
  • The revised offer throws in an 18.3% higher cash component as a sweetener. The offer implies a healthy acquisition multiple compared to peers.
  • The offer is subject to shareholder and regulatory approvals. At the last close price, the gross spread to the current offer value of A$5.635 per share is 13.7%.

HSI Properties, Link RIET, HSI Financials, China Merchants Bank, and ICBC

By Untying The Gordian Knot

  • At the beginning of the week, I was determined to have this post with a more bullish tone. Maybe it is a contrarian indicator.
  • But as of yesterday’s market, I see that my efforts were rather over-optimistic.
  • The note is what is in front of me rather than speculating we are at the change in trend.

Edelweiss: Credit Business Is Normalizing; Rest of the Businesses Are Scaling Up Well

By Ankit Agrawal, CFA

  • Edelweiss’ credit business is now normalizing with GNPA at 2.5% and NNPA at 1.8%. Credit costs came in negative as asset quality is improving and excess provisioning is being normalized. 
  • Rest of the businesses continue to scale up well. Edelweiss is among the fastest grower in the mutual fund and insurance businesses. Wealth Management business continues to do well.
  • At current valuation, Edelweiss is available cheap and as per our estimates, an investment in it has potential to more than quadruple by the end of FY25.

Road King – Earnings Flash – H1 FY 2022 Results – Lucror Analytics

By Leonard Law, CFA

Road King’s H1/22 results were acceptable in our view. The company reported robust EBITDA growth and strong margin expansion, likely supported by deliveries of the higher-margin Hong Kong projects sold in FY 2021. Net debt improved marginally, in line with the stronger earnings.

That said, Cash/ST Debt was inadequate at 0.8x. Road King may face a funding gap for repayment of its USD 358 mn bonds in February 2023, though it should be able to bridge the gap through better cash collections in H2/22 or potential external financing (asset sales or equity issuances). Positively, the company has a well-spread debt maturity profile, with only one offshore bond coming due in 2023 and the next (USD 480 mn) due in September 2024.


Morning Views Asia: Guangzhou R&F Properties

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Consumer: WM Motor Technology Co Ltd, Nike, Colgate Palmolive Co, Levi Strauss & Co and more

By | Consumer, Daily Briefs

In today’s briefing:

  • WM Motor Holding IPO – The Negatives – Has Ample Issues to Contend With
  • Nike Inc: Innovation For The Pregnant Women Niche & Other Drivers
  • Colgate-Palmolive: What Recent Results Mean For Long-Term Holders
  • Levi Strauss & Co: Collaboration With Reese Cooper & Other Drivers

WM Motor Holding IPO – The Negatives – Has Ample Issues to Contend With

By Sumeet Singh

  • WM Motor Technology Co Ltd (WMT CH) (WMM) is looking to raise about US$1bn in its upcoming Hong Kong IPO.
  • WM Motor is a smart EV player in China. As of the latest practicable date, it had a total of four main EV models. 
  • In this note, we talk about the not-so-positive aspects of the deal.

Nike Inc: Innovation For The Pregnant Women Niche & Other Drivers

By Ishan Majumdar

  • Nike Inc had another stellar quarter and managed to surpass Wall Street expectations in terms of revenues as well as earnings with plenty of new innovations coming out.
  • A new lifestyle show, Nike Spark Flynit, was launched that introduces the latest innovation of NIKE Running with the Spark cushioning system.
  • This quarter, in Jordan, Luka Doncic debuted his anticipated signature shoe Luka 1, during the NBA Playoff.

Colgate-Palmolive: What Recent Results Mean For Long-Term Holders

By Vladimir Dimitrov, CFA

  • Colgate-Palmolive (NYSE:CL) is hardly a business for risk-seeking and short-term oriented investors.
  • While the management has given us a master class in long-term value creation, the share price is also unlikely to make anyone rich quickly.
  • On the contrary, CL is an investment akin for anyone looking for steady value accumulation, superior risk-adjusted returns and a wide moat.

Levi Strauss & Co: Collaboration With Reese Cooper & Other Drivers

By Ishan Majumdar

  • Levi Strauss & Co continued to see a strong consumer demand in the last quarter as the management continued executing its strategic initiatives that are viewed clearly in the results.
  • Its strategic priorities continue to be focused on margin expansion with a direct-to-consumer (D2C) first approach.
  • We provide Levi Strauss with a ‘Buy’ rating and a revision in the target price.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars

Daily Brief Health Care: Ramsay Health Care, Bavarian Nordic A/S, Helixmith, Imugene Ltd, Abbott Laboratories and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Ramsay’s Overdue Update on the KKR Proposal
  • STOXX Europe Quiddity Leaderboard Sep 2022: 11 ADDs/DELs, Sandvik-Alleima, and More
  • Helixmith (084990 KS): Overhang on Phase 3 Clinical Trial Uncertainty Got Removed
  • Imugene (IMU AU): Clinical Trial Continued to Advance; Cash Position Still Strong
  • Abbott Laboratories: Capacity Expansion For Diabetes Care & Other Drivers

Ramsay’s Overdue Update on the KKR Proposal

By Arun George

  • Ramsay Health Care (RHC AU) notes that discussions with KKR are ongoing, but the indicative proposal is held up by due diligence access to Ramsay Generale de Sante (GDS FP).
  • KKR proposed an alternative proposal that the Board rejected as “meaningfully inferior.” KKR remains interested, and its shenanigans are likely a move to nudge down the price.
  • At the last close, the risk/reward profile is favourable as the downside due to a deal break (-3% estimated decline) is lower than the upside (+20%) to the indicative proposal.

STOXX Europe Quiddity Leaderboard Sep 2022: 11 ADDs/DELs, Sandvik-Alleima, and More

By Janaghan Jeyakumar, CFA

  • In this insight, we take a look at the names leading the race to become ADDs/DELs for the STOXX Europe 600 and EURO STOXX Indices for the September 2022 Rebalance.
  • Based on current rankings, there could be around 11 ADDs/DELs in the September 2022 Rebalance.
  • The completion of the Avast PLC (AVST LN) and Meggitt PLC (MGGT LN) deals could result in intra-review changes in September 2022.

Helixmith (084990 KS): Overhang on Phase 3 Clinical Trial Uncertainty Got Removed

By Tina Banerjee

  • Helixmith (084990 KS) shares have been sliding since end of June due to delay in receiving the recommendation from the U.S. data monitoring committee for its phase 3 clinical trial.
  • On August 18, Helixmith received recommendation to continue phase 3 clinical trial of its lead candidate Engensis (VM202) for diabetic peripheral neuropathy, thereby removing the overhang.
  • Engensis has attracted high interest from investors, as it is targeting a large addressable patient population of nearly 8.5 million in the U.S. alone, with high unmet medical need.  

Imugene (IMU AU): Clinical Trial Continued to Advance; Cash Position Still Strong

By Tina Banerjee

  • Imugene Ltd (IMU AU) has recently dosed the first patient in cohort 3 in the phase 1 clinical trial of oncolytic virotherapy candidate, CHECKvacc for breast cancer.
  • As at June 30, 2022, Imugene had cash balance of A$99.9 million, providing a runway to support its clinical pipeline and operations into 2025. 
  • As the clinical trials progressing, the company has appointed an experienced life sciences CFO.

Abbott Laboratories: Capacity Expansion For Diabetes Care & Other Drivers

By Ishan Majumdar

  • Abbott Laboratories had a strong financial performance in the recent quarter led by the development of medical, diagnostics, and pharmaceutical devices.
  • During this quarter, the company is continuing to strengthen its Medical Device portfolio with new innovative products.
  • In this report, we have carried out a fundamental analysis of the historical financial statements of the company.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars